Axsome Therapeutics Champions Brain Health During Alzheimer’s & Brain Awareness Month
NEW YORK, June 20, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era...
Disability
AARP Services Announces New AARP Member Benefits Launching This Summer
WASHINGTON, June 16, 2025 /PRNewswire/ -- Today, it has been announced that AARP members have the opportunity to take advantage of...
Access Ready Strategic Joins the Consortium for Constituents with Disabilities (CCD) and Other Organizations on Vital Policy and Public Interest Positions
Many Groups and Organizations respond on Policy Issues WASHINGTON, June 12, 2025 /PRNewswire/ -- The recent rapid approach to policy...
Positive PoNSTEP Study Results Presented at Consortium of Multiple Sclerosis Centers Annual Meeting
-PoNS Therapeutic Experience Program (PoNSTEP) study demonstrates durable long-term beneficial effects of PoNS Therapy® on gait deficit improvement in people...
Positive PoNSTEP Study Results Presented at Consortium of Multiple Sclerosis Centers Annual Meeting
-PoNS Therapeutic Experience Program (PoNSTEP) study demonstrates durable long-term beneficial effects of PoNS Therapy® on gait deficit improvement in people...
Pharmazz Inc. Secures $25 Million Strategic Equity Investment from Sun Pharmaceutical Industries Ltd.
Funding supports pivotal Phase 3 trial for sovateltide, a potential first-in-class therapy that could transform the treatment of acute cerebral...
Vivex® Biologics, Inc. Appoints Industry Veteran Jon E. Block, Ph.D., as Chief Clinical Officer
Dr. Jon Block to Lead Vivex’s Completion of its Ascend and Restore Randomized Clinical Trials for VIA Disc® NP, Vivex’s...
Sun Life partners with Wellthy to provide life insurance members with concierge care for end-of-life planning, loss and grief
WELLESLEY, Mass. and NEW YORK, June 9, 2025 /PRNewswire/ -- Sun Life U.S., a top ten group benefits provider, and...
TG Therapeutics Announces Data Presentations for BRIUMVI in Multiple Sclerosis at the 2025 Consortium of Multiple Sclerosis Centers Annual Meeting
NEW YORK, May 30, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the presentations of data highlighting...
Roche’s fenebrutinib maintains near-complete suppression of disease activity and disability progression for up to two years in people with relapsing multiple sclerosis
Patients on fenebrutinib had low relapse rates with data showing no active brain lesions or disability progression after nearly two...
RedMane Technology Names Nick Cronshaw to Sales Executive Role Focused on Global Health and Human Services Solutions
CHICAGO, May 29, 2025 /PRNewswire/ -- RedMane Technology appointed Nick Cronshaw to a Sales Executive position focused on advancing the...
World-Renowned Mold Illness Expert Dr. Scott McMahon Joins MoldCo as Medical Director
Together, They Aim to Solve One of America's Most Overlooked Health Crisis: Mold Toxicity LOS ANGELES, May 28, 2025 /PRNewswire/...
CEFALY Technology Introduces CEFALY@Work: A Workplace Wellness Initiative for Employees With Migraine
DARIEN, Conn., May 27, 2025 /PRNewswire/ -- Medical device maker CEFALY Technology today announced the launch of CEFALY@Work, a new offering...
CMHA National launches flexible mental health training for managers, ready for your LMS
TORONTO, May 27, 2025 /CNW/ - To meet the growing need for mental health training in workplaces, the Canadian Mental Health...
ANI Pharmaceuticals Announces Initiation of Phase 4 Clinical Trial of Purified Cortrophin® Gel for the Treatment of Acute Gout Flares
Purified Cortrophin Gel is the only ACTH therapy approved by the FDA for the treatment of acute gout flares Trial to...
Route 92 Medical Announces Results of SUMMIT MAX Clinical Trial Showing Highest First Pass Effect Ever Reported in a Randomized Endovascular Stroke Thrombectomy Study
Data from 250-patient, 31-center, randomized controlled trial presented at European Stroke Organisation Conference Three highest enrolling sites reported 96% delivery...
Applied Therapeutics Presents Full 12-Month Clinical Results and New Topline Data from INSPIRE Phase 2/3 Trial of Govorestat in CMT-SORD in Late-Breaking Oral Presentation at the Peripheral Nerve Society 2025 Annual Meeting
Slowing of progression of disease observed via MRI at 24 months Improvements in outcomes and reduction in sorbitol maintained through...
From Affordable Premiums to Holistic Care, Policybazaar Unveils Comprehensive Solutions for NRIs and Their Families in India
GURUGRAM, India, May 16, 2025 /PRNewswire/ -- Policybazaar, one of India's largest online insurance platforms, has launched, through its insurance...
accessiBe Forms Advisory Board and Testing Hub Comprised of Community Leaders and Disability Advocates to Drive Web Accessibility Product Innovation
Advisory Groups Launch on Global Accessibility Awareness Day (GAAD) NEW YORK, May 15, 2025 /PRNewswire/ -- Web accessibility market leader accessiBe,...
CEFALY to Demonstrate Its Migraine Treatment Device at the American College of Obstetricians and Gynecologists’ Annual Clinical & Scientific Meeting
DARIEN, Conn., May 13, 2025 /PRNewswire/ -- Medical device maker CEFALY Technology will be conducting live demonstrations of its clinically...